Making the Immune System Programmable.
We programme T-cell engagers that cancer cannot outrun.
Requires tumour cells to lose two independent antigens to escape therapy — each evolutionary step carrying its own fitness cost.
Every candidate evaluated on T-cell killing, activation, and cytokine profiles in primary human immune cells — not binding assays.
Four programmes across myeloma, solid tumours, autoimmune disease, and AML — the same discovery engine, encoding different immune instructions.
The kill event.
A T-cell engager bridges T cell and tumour cell — activating a targeted immune response. Precise. Programmable. Repeatable.
The molecule
We programme bispecific and trispecific engagers that redirect T cells against two independent tumour targets simultaneously.
Trispecific · Bispecific · VHH-based · One modular platform
The data
Our AI trains on T-cell killing, activation, and cytokine profiles measured in primary human immune cells — not binding assays.
Up to 1 million candidates screened per experiment
The escape resistance
Our OR-gate architecture requires tumour cells to lose both independent antigens to evade therapy — structurally harder to escape than any single-target approach.